Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread

por Hung-Chih Hsu, Kuo-Cheng Huang, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Tsai-Sheng Yang, Chien-Chih Chen, Yee Chao, Hao-Wei Teng
Publicado 2021

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment

por Hong-Hwa Chen, Tao-Wei Ke, Ching-Wen Huang, Ching-Wen Huang, Jeng-Kae Jiang, Chou-Chen Chen, Yao-Yu Hsieh, Hao-Wei Teng, Bo-Wen Lin, Yi-Hsin Liang, Yu-Li Su, Hung-Chih Hsu, Feng-Che Kuan, Yenn-Hwei Chou, Johnson Lin, Ben-Ren Lin, Yu-Yao Chang, Jaw-Yuan Wang, Jaw-Yuan Wang, Jaw-Yuan Wang, Jaw-Yuan Wang
Publicado 2021